Rafael Holdings, Inc. (RFL)

NYSE: RFL · IEX Real-Time Price · USD
1.720
0.00 (0.00%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Company Description

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel.

It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells.

Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.

The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors.

In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation.

Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

Rafael Holdings, Inc.
Rafael Holdings logo
Country United States
Industry Real Estate Services
Sector Real Estate
Employees 13
CEO William Conkling

Contact Details

Address:
520 Broad Street
Newark, New Jersey 07120
United States
Phone 212-658-1450
Website rafaelholdings.com

Stock Details

Ticker Symbol RFL
Exchange NYSE
Fiscal Year August - July
Reporting Currency USD
CIK Code 0001713863
CUSIP Number 75062E106
ISIN Number US75062E1064
Employer ID 82-2296593
SIC Code 6500

Key Executives

Name Position
Howard S. Jonas Founder and Executive Chairman
William Conkling Chief Executive Officer and President
David A. Polinsky Esq. Chief Financial Officer
Barbara A. Ryan Investor Relations Officer
Gus Kodersha Chief Technical Operations Officer
Dr. Rick Ewing Head of Drug Discovery
Dr. John Mayer Goldberg M.D. Chief Medical Officer
Joyce J. Mason Esq. Corporate Secretary

Latest SEC Filings

Date Type Title
Mar 14, 2024 10-Q Quarterly Report
Mar 14, 2024 8-K Current Report
Mar 13, 2024 8-K Current Report
Jan 16, 2024 8-K Current Report
Dec 14, 2023 10-Q Quarterly Report
Dec 14, 2023 8-K Current Report
Nov 20, 2023 DEFR14A Filing
Nov 20, 2023 DEF 14A Other definitive proxy statements
Oct 30, 2023 10-K Annual Report
Oct 30, 2023 8-K Current Report